

Zosano Pharma Corp  
Form 8-K  
July 06, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): July 2, 2015**

**ZOSANO PHARMA CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36570**  
**(Commission**  
  
**File Number)**  
**34790 Ardentech Court**  
  
**Fremont, CA 94555**

**45-4488360**  
**(I.R.S. Employer**  
  
**Identification No.)**

Edgar Filing: Zosano Pharma Corp - Form 8-K  
(Address of principal executive offices) (Zip Code)

(510) 745-1200

Registrant's telephone number, including area code

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On July 6, 2015, we issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing that Novo Nordisk A/S has notified us of its intention to not continue the Collaboration, Development and License Agreement dated January 31, 2014 between Novo Nordisk A/S and our wholly owned subsidiary, ZP Opco, Inc.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit</b>	<b>Description</b>
99.1	Press release dated July 6, 2015, entitled Zosano Pharma Announces Discontinuation of Novo Nordisk GLP-1 Patch Collaboration

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZOSANO PHARMA CORPORATION**

Dated: July 6, 2015

By: /s/ Vikram Lamba  
Name: Vikram Lamba  
Title: President and Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	Press release dated July 6, 2015, entitled Zosano Pharma Announces Discontinuation of Novo Nordisk GLP-1 Patch Collaboration